Enigma news, latest stories & analysis

Find today's trending Enigma news & headlines

Allakos Inc. down 80% after announcing topline phase III results from its Enigma II clinical study
Allakos Inc. down 80% after announcing topline phase III results from its Enigma II clinical study
  • The researchers did Enigma II study in 24 weeks of randomized placebo-controlled research of lirentelimab.
  • Both the Kryptos and Enigma studies met all their co-primary endpoints.
  • Safety data were also generally consistent.
December 22, 2021